Literature DB >> 16622155

Performance of drug-drug interaction software for personal digital assistants.

Natalie A Perkins1, John E Murphy, Daniel C Malone, Edward P Armstrong.   

Abstract

BACKGROUND: Personal digital assistants (PDAs) allow healthcare professionals to check for potential drug-drug interactions (DDIs) at the point of care, reducing the need to consult traditional references. However, PDAs can only be as effective as the software programs they use.
OBJECTIVE: To examine the ability of DDI software programs manufactured for Palm OS-compatible PDAs in detecting clinically important DDIs.
METHODS: Eight PDA software programs were assessed for sensitivity, specificity, and positive and negative predictive values for 16 well-documented DDIs contained within 6 simulated patient profiles.
RESULTS: Sensitivity of the software programs ranged from 0.81 to 1.0, specificity ranged from 0.52 to 1.0, positive predictive values ranged from 0.62 to 1.0, and negative predictive values ranged from 0.88 to 1.0. Five programs scored perfect sensitivity scores: DrugIx, ePocrates Rx, ePocrates Rx Pro, Lexi-Interact, and the Tarascon pocket Pharmacopoeia. Of these, the ePocrates programs scored the highest in specificity (0.9), while Lexi-Interact and the Tarascon pocket Pharmacopoeia scored considerably lower (0.52). MosbyIx was the only program to score a 1.0 in specificity; however, its sensitivity was just 0.81.
CONCLUSIONS: ePocrates Rx and ePocrates Rx Pro scored greater than or equal to 90% in regard to both sensitivity and specificity, making them the most reliable in detecting the clinically relevant interactions studied without the distraction of detecting those of no clinical significance. In addition, ePocrates Rx is updated regularly and is easily accessible on the Internet at no cost.

Entities:  

Mesh:

Year:  2006        PMID: 16622155     DOI: 10.1345/aph.1G603

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  8 in total

1.  A high-speed drug interaction search system for ease of use in the clinical environment.

Authors:  Masahiro Takada; Hiroshi Inada; Kazuo Nakazawa; Shoko Tani; Michiaki Iwata; Yoshihisa Sugimoto; Satoru Nagata
Journal:  J Med Syst       Date:  2012-03-03       Impact factor: 4.460

2.  Evaluation of three brands of drug interaction software for use in intensive care units.

Authors:  Adriano Max Moreira Reis; Silvia Helena De Bortoli Cassiani
Journal:  Pharm World Sci       Date:  2010-10-21

3.  Potential drug-drug interactions on in-patient medication prescriptions at Mbarara Regional Referral Hospital (MRRH) in western Uganda: prevalence, clinical importance and associated factors.

Authors:  S J Lubinga; E Uwiduhaye
Journal:  Afr Health Sci       Date:  2011-09       Impact factor: 0.927

4.  [Mobile and digital documentation of inpatient treatments : use of personal digital assistants in addition with the ClinicCoach(c) software].

Authors:  K Homayounfar; J Spiller; F von Stillfried; M Raible
Journal:  Unfallchirurg       Date:  2007-12       Impact factor: 1.000

5.  Physician intervention for medication reduction in a nursing home: the polypharmacy outcomes project.

Authors:  Bruce K Tamura; Christina L Bell; Karen Lubimir; Wendy N Iwasaki; Laura A Ziegler; Kamal H Masaki
Journal:  J Am Med Dir Assoc       Date:  2010-10-20       Impact factor: 4.669

Review 6.  Treatment considerations for elderly and frail patients with neuropathic pain.

Authors:  Kenneth E Schmader; Ralf Baron; Maija L Haanpää; John Mayer; Alec B O'Connor; Andrew S C Rice; Brett Stacey
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

7.  Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.

Authors:  Julie C Lauffenburger; Christina L Mayer; Roy L Hawke; Kim L R Brouwer; Michael W Fried; Joel F Farley
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-10       Impact factor: 2.566

8.  Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross-Sectional Descriptive Study as Part of the PharmLines Initiative.

Authors:  Muh Akbar Bahar; Jens H J Bos; Sander D Borgsteede; Aafje Dotinga; Rolinde A Alingh; Bob Wilffert; Eelko Hak
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.